Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-Meldung: Gleich zu Wochenbeginn prozentual dreistellig? Der frühe Vogel…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZ0Z | ISIN: US00887A2042 | Ticker-Symbol: 015A
NASDAQ
26.03.25
20:36 Uhr
1,760 US-Dollar
-0,010
-0,56 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REIN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
REIN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,5301,66028.03.

Aktuelle News zur REIN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.02.Vision Marine Technologies Inc: Vision Marine Expands Partnership With Aileron Residences to Launch Electric Boat Rentals and Retail Hub in South Florida357MONTRÉAL, QC / ACCESS Newswire / February 12, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) ("Vision Marine" or the "Company"), a company specializing in electric marine propulsion, announces...
► Artikel lesen
16.01.Aileron straps in for 2025 with a new name: Rein Therapeutics3
10.01.Rein Therapeutics, Inc. - 8-K, Current Report-
10.01.Aileron Therapeutics Rebrands As Rein Therapeutics2
10.01.Aileron Therapeutics announces rebranding to Rein Therapeutics1
10.01.Aileron Therapeutics Announces Rebranding to Rein Therapeutics90Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assetsCompany...
► Artikel lesen
15.11.24Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.025
14.11.24Aileron Therapeutics, Inc.: Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights121Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients...
► Artikel lesen
REIN THERAPEUTICS Aktie jetzt für 0€ handeln
13.11.24Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis1
13.11.24Aileron Therapeutics meldet vielversprechende Ergebnisse der Phase-1b-Studie für IPF-Behandlung1
13.11.24Aileron Therapeutics, Inc.: Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)121High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts...
► Artikel lesen
31.10.24Aileron Therapeutics, Inc.; Advancium Health Network: Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma115Agreement marks first of its kind for Advancium, a public charity launched by Deerfield Management and the Deerfield FoundationAdvancium will evaluate ALRN-6924 as a potential therapy for...
► Artikel lesen
23.09.24Aileron Therapeutics, Inc.: Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)124Cohort 2 will evaluate high-dose LTI-03 (5 mg BID) Previously announced Cohort 1 data demonstrated positive trends in seven of the eight biomarkers evaluated, suggesting a potential therapeutic effect ...
► Artikel lesen
15.08.24Aileron Therapeutics, Inc.: Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights418Announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03 evaluating low dose LTI-03 (2.5 mg BID) in idiopathic pulmonary fibrosis ("IPF") patients, with positive trends...
► Artikel lesen
15.05.24Aileron Therapeutics, Inc.: Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights216Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated...
► Artikel lesen
01.05.24Aileron Therapeutics, Inc.: Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)130Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of...
► Artikel lesen
15.04.24Aileron Therapeutics, Inc.: Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update672Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1